Fibrovein

Patient Information Leaflet

Fibrovein, 0.2%, 0.5%, 1% and 3%, solution for injection
Natrii tetradecylis sulfas
Please read this leaflet carefully before using this medicine, as it contains
important information for you.
Keep this leaflet, as you may need to read it again.
If you have any further questions, please consult your doctor or nurse.
If you experience any serious adverse reactions, including any not listed in this leaflet,
inform your doctor or nurse immediately.
See section 4.
Table of Contents

1. What Fibrovein is and what it is used for
2. What you need to know before using Fibrovein
3. How to use Fibrovein
4. Possible side effects
5. How to store Fibrovein
6. Contents of the pack and other information

1. What Fibrovein is and what it is used for

Fibrovein contains the active substance sodium tetradecyl sulfate.
Fibrovein is available in various concentrations and is used in the treatment of varicose veins, as well as large, medium, and small dilated capillaries and spider veins.
The active substance belongs to a group of medicines known as sclerosing agents. Sclerosing agents are chemical substances which, when injected into a diseased vein, cause swelling of its inner lining and adhesion of its walls. Blood flow through the vein becomes impossible, and eventually fibrosis (scar tissue formation) occurs. After several weeks, the vein usually becomes no longer visible.
Fibrovein is intended for use in adults only.

2. Important information before using Fibrovein

When not to use Fibrovein:

• if the patient has a known allergy to sodium tetradecyl sulfate or to any of the other ingredients of this medicine (listed in section 6) or if the patient has an allergic condition;
• if the patient is unable to walk for any reason or is seriously ill;
• if the patient is at risk of developing blood clots in the venous system due to:
• a hereditary blood disorder, e.g. thrombophilia;
• use of hormonal contraceptives or hormone replacement therapy;
• significant obesity;
• smoking;
• prolonged immobilization;
• if the patient has recently experienced blood clots in superficial or deep veins or in the lungs;
• if the patient has recently undergone surgery;
• if the patient has varicose veins caused by pelvic or abdominal tumours, unless the tumour has been removed;
• if the patient has an uncontrolled systemic disease such as diabetes, hyperthyroidism, asthma, blood abnormalities, blood infection, or recent skin disorders or breathing difficulties;
• if the patient has swelling or redness of the skin, warm or tender to touch (phlebitis);
• if the patient has any infection;
• if the patient has a progressive tumour;
• if the patient has abnormal closure of deep vein valves (valvular insufficiency);
• if the patient has an arterial embolism;
• if the patient has acute inflammation of the leg veins (acute phlebitis);
• if the patient has a symptomatic heart defect (only when the sclerosant is administered in foam form).

Warnings and precautions
Before starting treatment with Fibrovein, discuss with the doctor if:
the patient is allergic to any foods or medications, or has any other allergies; in such case, the patient should consult the doctor to receive a test dose 24 hours before further treatment;
the patient has previously experienced blood clots in superficial or deep veins or in the lungs;
the patient has a symptomatic heart defect (in case of foam sclerosant administration);
the patient has a symptomatic heart defect (in case of foam sclerosant administration);
the patient suffers from migraines;
if the patient has venous disorders in the legs, associated with a chronic condition causing tissue swelling (lymphatic oedema). Fibrovein may increase local pain and inflammation for several days or weeks;
the patient has previously suffered from pulmonary hypertension;
the patient has experienced a transient ischaemic attack (TIA), stroke, or serious cerebrovascular event;
the patient has been diagnosed with arterial or venous disease (atherosclerosis);
the patient has been diagnosed with thrombosis and inflammation of arteries and veins in hands and feet (Buerger's disease);
the patient has breathing difficulties controlled by medication (asthma).
Fibrovein must be administered only by a physician, and if national guidelines permit, it may be administered under a physician's supervision by appropriately trained medical personnel experienced in venous anatomy and familiar with proper injection techniques. Prior to the procedure, the physician may assess the patient's venous valve function.
Before starting the procedure, the physician will ask the patient several questions about their health status and provide information about potential adverse effects associated with the procedure.
During treatment
The physician will monitor the patient during and after the sclerotherapy procedure for hypersensitivity reactions (redness, itching, coughing) or neurological symptoms (visual disturbances, migraines, tingling or numbness).
The physician will schedule a follow-up visit for the patient.
Children and adolescents
The safety and efficacy of Fibrovein in children and adolescents have not been established.
Fibrovein and other medicines
If the patient is taking hormonal contraceptives ("the pill") or using hormone replacement therapy, she may be at increased risk of developing venous thrombosis (see “When not to use Fibrovein”). Inform the doctor or nurse about this.
Inform the doctor or nurse about all medicines currently taken or recently used, as well as any medicines the patient plans to take, including those available without a prescription.
Pregnancy and breastfeeding
The patient should inform the doctor if:
she is pregnant or suspects she may be pregnant;
she plans to become pregnant;
she is breastfeeding.
The safety of Fibrovein during pregnancy has not been established. Fibrovein should not be used in pregnant women unless clearly necessary. The physician will decide whether Fibrovein treatment is appropriate for the patient.
It is unknown whether Fibrovein passes into breast milk. If the patient is breastfeeding, the physician will decide whether Fibrovein is appropriate for her.
Driving and operating machinery
After administration of Fibrovein, to reduce the risk of inflammation and skin discolouration, the physician may recommend appropriate leg bandaging and/or wearing compression stockings, which may affect the ability to drive.
Fibrovein contains sodium, potassium and benzyl alcohol
This medicine contains:
less than 1 mmol (23 mg) of sodium per vial/ampoule, meaning the medicine is considered "sodium-free";
less than 1 mmol (39 mg) of potassium per vial/ampoule, meaning the medicine is considered "potassium-free";
40 mg of benzyl alcohol in each 2 ml ampoule or 100 mg of benzyl alcohol in each 5 ml vial, equivalent to 20 mg/ml. Benzyl alcohol may cause allergic reactions. Consult a doctor or pharmacist if pregnant, breastfeeding, or if the patient has liver or kidney disease, as benzyl alcohol may accumulate in the body and cause adverse effects (so-called "metabolic acidosis").

3. How to use Fibrovein

Do not attempt to self-inject Fibrovein. Treatment must always be performed by an experienced physician trained in proper injection techniques.
The treatment involves very careful and slow injection of the drug, using the finest needles available, directly into the diseased veins, enabling removal of blood from them. The drug may be manually mixed using two syringes and a three-way tap to create a mixture with air and produce a foam, which helps remove blood from larger veins. In such cases, the drug must be administered by a physician trained in the correct techniques for producing and administering the drug in foam form.
When treating invisible varicose veins of the lower limbs and for foam sclerotherapy, the procedure should be performed under ultrasound (USG) guidance.
The physician will decide which concentration of Fibrovein to use and which areas to treat. Recommended doses:
Adults and elderly patients

• from 0.1 ml to 2 ml of Fibrovein per injection. The physician may administer up to 10 ml of the three lower concentrations of Fibrovein, but no more than 4 ml when using the highest concentration.

Due to limitations regarding the maximum daily dose of sclerosant, the procedure may need to be repeated several times.
After completion of treatment with Fibrovein, follow your physician's instructions. The physician may recommend appropriate leg bandaging and/or wearing compression stockings to reduce the risk of inflammation and skin discoloration.
If you have any further doubts concerning the use of this medicine, consult your physician or nurse.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Serious adverse reactions may occur. Treatment with Fibrovein must be discontinued
and you should immediately contact your doctor or go to the nearest hospital emergency department
if any of the following symptoms occur:

Uncommon (may occur in up to 1 in 100 people)

• Blood clots in deep veins (deep vein thrombosis, most likely caused by the underlying disease). Symptoms include pain, swelling and tenderness in one leg (usually in the calf), severe pain in the affected area, increased warmth of the skin at the site of the clot or redness of the skin, particularly at the back of the leg below the knee.

Rare (may occur in up to 1 in 1,000 people)

• Local necrosis of skin tissue or, less frequently, nerves. Symptoms include pain, change in skin colour (redness), swelling or fluid accumulation, blisters on the skin (which may be filled with clear fluid or blood), dark red, purple or black skin colour, abnormal sensations (tingling, pricking, burning), numbness or loss of sensation.

Very rare (may occur in up to 1 in 10,000 people)

• The most serious adverse reaction is a severe allergic reaction (anaphylactic shock), which may cause difficulty breathing or a sudden drop in blood pressure, leading to a feeling of fainting or loss of consciousness. Anaphylactic shock is rare but may be fatal; therefore, appropriate treatment must be administered immediately if it occurs.
• Arterial blockage caused by a blood clot, which may lead to:

o stroke or interruption of blood flow to the brain or eye (transient ischaemic attack).
Symptoms may include weakness, numbness or paralysis of the face, arm or leg,
usually on one side of the body, slurred or distorted speech or difficulty
understanding others, blindness in one or both eyes or double vision.
o pulmonary embolism. Symptoms may include sudden shortness of breath, sudden sharp chest
pain which may worsen during deep breathing or coughing, rapid heartbeat or increased
respiratory rate.
To protect patients from this very rare adverse reaction, this medicine must not be used
in patients who have an increased risk of developing blood clots in veins and arteries (thrombosis risk).

• Circulatory failure. Symptoms may include feeling tired, dizziness, fainting, chest pain, shortness of breath, weakness, dizziness, vomiting and palpitations.
• Tissue necrosis following intra-arterial injection. Symptoms may vary depending on the amount of medicine injected, the injection site and the speed of medical intervention. These may range from pain without long-term damage to loss of large areas of tissue, including the foot, which may lead to the need for limb amputation.

Other adverse reactions that may occur include:
Very common (may occur in more than 1 in 10 people):

• Superficial phlebitis.

Common (may occur in up to 1 in 10 people)

• Pain or burning (short-term at the injection site);
• Skin pigmentation;
• Dilation of subcutaneous capillaries at the injection site (so-called matting).

Uncommon (may occur in up to 1 in 100 people):

• Local allergic or non-allergic skin reactions, e.g. redness, itching, rash or swelling;
• Visual disturbances;
• Migraine.

Rare (may occur in up to 1 in 1,000 people):

• Cough, shortness of breath, feeling of pressure or tightness in the chest;
• Burning, tingling, pricking or itching of the skin;
• Headache, feeling of fainting;
• Disorientation, dizziness, loss of consciousness.

Very rare (may occur in up to 1 in 10,000 people):

• Fever, hot flushes, red itchy skin (urticaria);
• Nausea, vomiting, diarrhoea, sensation of a swollen or enlarged tongue, dryness of the mouth;
• Phlebitis.

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or nurse. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the responsible entity.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Fibrovein

Keep this medicine out of sight and reach of children.
There are no special requirements regarding storage temperature.

• Do not freeze.
• Protect from light by storing vials and ampoules in the outer packaging.
• Do not use this medicine after the expiry date stated on the cardboard box after: "EXP". The expiry date refers to the last day of the stated month.

For single use only. The contents of the container should be used immediately after opening.
Any unused portion of the product must be discarded.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Such measures help protect the environment.

6. Contents of the pack and other information

What Fibrovein contains
The active substance is sodium tetradecyl sulfate.
For the 0.2% concentration:
Each ml of injection solution contains 2 mg of sodium tetradecyl sulfate.
Each 5 ml vial contains 10 mg of sodium tetradecyl sulfate.
For the 0.5% concentration:
Each ml of injection solution contains 5 mg of sodium tetradecyl sulfate.
Each 2 ml ampoule contains 10 mg of sodium tetradecyl sulfate.
For the 1% concentration:
Each ml of injection solution contains 10 mg of sodium tetradecyl sulfate.
Each 2 ml ampoule contains 20 mg of sodium tetradecyl sulfate.
For the 3% concentration:
Each ml of injection solution contains 30 mg of sodium tetradecyl sulfate.
Each 2 ml ampoule contains 60 mg of sodium tetradecyl sulfate.
Each 5 ml vial contains 150 mg of sodium tetradecyl sulfate.
Other ingredients are: benzyl alcohol (20 mg/ml), disodium phosphate dodecahydrate, potassium dihydrogen phosphate, water for injections, sodium hydroxide (for pH adjustment). See section 2, "Fibrovein contains sodium and potassium".

What Fibrovein looks like and contents of the pack
Fibrovein is a solution for injection supplied in glass ampoules or vials. The solution is clear, colourless, sterile, and free from visible solid particles.
Fibrovein, 0.2%: pack contains 2, 5 or 10 vials of 5 ml each.
Fibrovein, 0.5%: pack contains 5 ampoules of 2 ml each.
Fibrovein, 1%: pack contains 5 ampoules of 2 ml each.
Fibrovein, 3%: pack contains 5 ampoules of 2 ml each or 2, 5 or 10 vials of 5 ml each.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder:
STD Pharmaceutical (Ireland) Limited
Block 1, Blanchardstown Corporate Park, Ballycoolen Road, Blanchardstown, Dublin 15
D15 AKK1, Ireland
+353 1588 6916

Manufacturer:
Medipha Sante
Les Fjords-Immeuble Oslo
19 Avenue de Norvege
91953 Courtaboeuf CEDEX
France
Chemische Fabrik Kreussler & Co. GmbH
Rheingaustrasse 87-93
65203 Wiesbaden,
Germany

This medicinal product is authorised in the European Economic Area under the following names:
Bulgaria, Czech Republic, France, Germany, Fibrovein
Ireland, Netherlands, Poland, Romania
Austria, Spain Veinfibro

Other sources of information:
Detailed information on this medicinal product is available on the website of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
www.urpl.gov.pl

Information intended exclusively for medical professionals:

Fibrovein, 0.2%, solution for injection
Fibrovein, 0.5%, solution for injection
Fibrovein, 1%, solution for injection
Fibrovein, 3%, solution for injection
Additional information regarding this product can be found in the Summary of Product Characteristics (SmPC).

Dosage and method of administration

Dosage
The medicinal product Fibrovein is intended for intravenous use only. Depending on the size and severity of venous lesions, different concentrations are required. Spider veins should be treated only with the 0.2% concentration, and reticular veins with 0.5%. The 1% concentration is most suitable for small and medium varicose veins, while the 3% concentration is indicated for larger venous lesions. The size of non-visible varicose veins should be determined under ultrasound (USG) guidance.

The sclerosing agent should be administered intravenously in small, equal portions along the course of the diseased vein. Fibrovein at concentrations of 0.2% and 0.5% should be administered in liquid form. Fibrovein at concentrations of 1% and 3% may be administered either as a liquid sclerosant or as a mixture of sclerosant with air (foam form), according to the description provided in the table below. The aim of the procedure is to achieve optimal destruction of the vessel walls using the sclerosant at the minimal effective concentration required for successful treatment. Excessively high concentrations of the medicinal product may lead to tissue necrosis or other complications.

Adults

*Total volume of fluid and air
In cases where particular caution is required, it is recommended to perform a sensitivity test by
administering to the patient 0.25 to 0.5 ml of the medicinal product Fibrovein and observing the patient for
several hours, followed by administration of a second or higher dose.
The procedure often requires repetition (on average, the patient requires 2 to 4 additional procedures)
due to the limited dose that can be applied during a single procedure. To protect the patient
from an allergic reaction, a small test dose of the medicinal product Fibrovein is recommended at the beginning of each procedure.
Fibrovein, 1% and 3% solution for injection
In case of administration of the sclerosing agent in foam form
Foam intended for treatment of larger veins can be prepared using the medicinal product
Fibrovein at concentrations of 1% and 3%. The foam must be prepared immediately before administration. It must be
administered to the patient by a physician adequately trained in the proper techniques
of producing and administering the medicinal product in foam form. Ideally, foam sclerotherapy
should be performed under ultrasound (USG) control.
Fibrovein, 0.2% solution for injection
For spider veins, the smallest possible needles (e.g., 30 G) should be used for injection, and the medicinal product should be injected slowly to allow blood to be displaced from the treated venous vessels. The treatment of spider veins may also use the so-called air-block technique involving additional air injection.
Elderly patients
There are no special dosing recommendations.
Children and adolescents
The safety and efficacy of the medicinal product Fibrovein in children and adolescents have not been established. Lack of data.
Method of administration
Below are instructions for preparing the foam. The method presented is the Tessari technique. Other techniques (e.g., DSS, Easyfoam, Sterivein) may also be used.
When preparing Fibrovein for administration, strict aseptic conditions must be maintained.
The Fibrovein medicinal product is intended for single use and parenteral administration. After opening
the vial or ampoule, the product must be used immediately, and any unused solution must be discarded.
Before use, visual inspection for the presence of solid particles should be performed. If
the solution contains solid particles, it must not be used.
Ideally, foam sclerotherapy should be performed under ultrasound (USG) control. In such a case,
the product must be administered by a physician adequately trained in the proper
techniques of producing and administering the medicinal product in foam form.
Pharmaceutical incompatibilities
This medicinal product must not be mixed with heparin.
Do not mix the medicinal product with other medicinal products, as compatibility studies have not been conducted.
Special warnings and precautions
Fibrovein must be administered exclusively by a physician; however, if national guidelines permit, it may be administered under physician supervision by appropriately qualified medical personnel experienced in venous system anatomy, diagnosis and treatment of venous diseases, and familiar with proper injection techniques.
Allergic reactions, including anaphylactic shock, have been reported; therefore, the physician administering this product must be prepared to initiate anti-shock treatment.
During the procedure, the physician must have immediate access to emergency resuscitation equipment.
Due to the need for special caution, the patient should be treated in a hospital setting.
Serious local adverse reactions, including tissue necrosis, may occur in case of extravasation; therefore, particular care must be taken during needle insertion, and the minimum effective dose should be injected at each injection site. The solution should be injected slowly.
Particular care must be taken to avoid injecting the solution into an artery, as this may cause tissue necrosis, potentially leading to limb amputation.
Special caution is required when performing injections in the foot and above and below the ankle ( malleolus ) due to the risk to one of the arteries. Compression should be applied when treating smaller veins, as the likelihood of pigmentation may be higher if blood extravasation occurs at the injection site.
Foam preparation and injection preparation
General recommendations
Foam quality depends on specific conditions:
Concentration of the product: Foam can be prepared only using sodium tetradecyl sulfate
at concentrations from 1% to 3%.
Ratio of fluid to air: Usually, this ratio is 1 volume of liquid to 3 to 4 volumes of air.
Number of transfers between syringes: The physician should follow the number of transfers specified for each technique.
Macroscopic consistency of the foam: The foam quality should be checked outside the syringe before administration. The foam should be uniform, soft, and cohesive, without visible large bubbles.
If the foam contains large bubbles, it must be discarded and a new foam prepared.
Total foam preparation time: Foam preparation should take approximately 10 seconds from the first to the last transfer of fluid between syringes.
Maximum time between foam preparation and injection: The sclerosing foam must be used within sixty seconds after preparation. After sixty seconds, any unused foam remnants must be discarded. If needed, more foam should be prepared.
Foam preparation (Tessari technique)
Strict aseptic conditions must be maintained during foam preparation.
To produce foam, 1 ml of liquid sclerosant is drawn into one sterile syringe and 3 ml or 4 ml of sterile air into a second sterile syringe. Air is drawn into the syringe through a 0.2 μm sterilizing filter, ensuring its sterility. The syringes are connected using a sterile three-way tap/connector (Fig. 1). Use of Luer Lock syringes and eye protection is recommended during foam preparation. Connecting a syringe with a Luer slip fitting to a three-way tap under pressure may fail, leading to uncontrolled leakage of the product.
After connecting the syringes, the sclerosant/air mixture is dynamically transferred approximately 20 times between the syringes through the three-way connector until a uniform, smooth foam consistency is achieved (Figs. 2 and 3).
The syringe containing the foam is then disconnected from the connector, and the venous puncture is immediately performed using this syringe to administer the foam into the vessel (Fig. 4).
The sclerosing foam must be used within sixty seconds after preparation. After sixty seconds, any unused foam remnants must be discarded. If needed, more foam should be prepared.
Before administration, the foam quality should be checked. The foam should have a uniform consistency, be white in color, and not contain visible large bubbles to the naked eye.

Excipients
This medicinal product contains:
less than 1 mmol (23 mg) of sodium per vial/ampoule, meaning the medicine is considered "sodium-free".
less than 1 mmol (39 mg) of potassium per vial/ampoule, meaning the medicine is considered "potassium-free".
40 mg of benzyl alcohol in each 2 ml ampoule or 100 mg of benzyl alcohol in each 5 ml vial, corresponding to 20 mg/ml. Benzyl alcohol may cause allergic reactions. It may cause metabolic acidosis in cases of pregnancy, breastfeeding, or liver or kidney disease.